2018
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial
Lansky A, Wijns W, Xu B, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachojannis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Baumbach A, Investigators T. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. The Lancet 2018, 392: 1117-1126. PMID: 30190206, DOI: 10.1016/s0140-6736(18)31649-0.Peer-Reviewed Original ResearchConceptsLate lumen lossStent late lumen lossTarget lesion failureCoronary artery diseaseNon-inferiority trialXience groupPrimary endpointLesion failureLumen lossAbluminal grooveAngiographic substudyComers populationArtery diseaseMyocardial ischaemiaMyocardial infarctionIschaemia-driven target lesion revascularisationAsymptomatic coronary artery diseaseTarget vessel myocardial infarctionIschemic coronary artery diseaseST-elevation myocardial infarctionRandom block allocationTarget lesion revascularisationStent thrombosis ratesVessel myocardial infarctionElevation myocardial infarction
2011
Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial.
Hermiller JB, Nikolsky E, Lansky AJ, Applegate RJ, Sanz M, Yaqub M, Sood P, Cao S, Sudhir K, Stone GW. Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroIntervention 2011, 7: 307-13. PMID: 21729832, DOI: 10.4244/eijv7i3a54.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsPercutaneous coronary interventionSegment restenosisYounger patientsElderly patientsLower incidenceSegment late lumen lossSegment late lossSPIRIT III trialTarget vessel failureLate lumen lossDrug-eluting stentsYears of ageThree-year resultsLower ratesAge-specific mechanismsStent assignmentAngiographic outcomesCoronary interventionIII trialsInducible ischaemiaEE patientsPE patientsLumen lossNeointimal response
2009
The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) Trial
Verheye S, Agostoni P, Dawkins KD, Dens J, Rutsch W, Carrie D, Schofer J, Lotan C, Dubois CL, Cohen SA, Fitzgerald PJ, Lansky AJ. The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) Trial. JACC Cardiovascular Interventions 2009, 2: 205-214. PMID: 19463427, DOI: 10.1016/j.jcin.2008.12.011.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsMajor adverse cardiac event ratesAdverse cardiac event ratesSingle de novo lesionsMajor adverse clinical eventsStent late lumen lossEnd pointBinary angiographic restenosisCardiac event ratePrimary end pointSecondary end pointsDe novo lesionsRandomized multicenter trialAdverse clinical eventsStent late lossLate lumen lossNative coronary arteriesStent restenosis rateBare metal stentsAngiographic restenosisNovo lesionsCoronary angiographyMulticenter trialRestenosis rateLumen loss
2006
The randomised study of the double dose versus single dose sirolimus-eluting stent for the treatment of diabetic patients with de novo coronary lesions.
Costa RA, Sousa JE, Abizaid A, Chaves A, Feres F, Sousa AG, Musumeci G, Mehran R, Fitzgerald PJ, Lansky AJ, Leon MB, Shiran A, Halon DA, Lewis BS, Guagliumi G. The randomised study of the double dose versus single dose sirolimus-eluting stent for the treatment of diabetic patients with de novo coronary lesions. EuroIntervention 2006, 2: 295-301. PMID: 19755304.Peer-Reviewed Original ResearchDe novo coronary lesionsSirolimus-eluting stentsNovo coronary lesionsDiabetic patientsCoronary lesionsDouble doseRevascularisation ratesStent late lumen lossLesion revascularisation rateDouble-blind fashionLate lumen lossBare metal stentsIncomplete stent appositionBinary restenosisPrimary endpointStent thrombosisLumen lossLate thrombosesNeointimal proliferationProcedure successNeointimal volumeNeointimal hyperplasiaPatientsMetal stentsBlind fashionSafety of beta radiation exposure to the non-target segment: an intravascular ultrasound dosimetric analysis.
Kaneda H, Honda Y, Morino Y, Fox T, Crocker I, Lansky AJ, Yock PG, Bonan R, Fitzgerald PJ. Safety of beta radiation exposure to the non-target segment: an intravascular ultrasound dosimetric analysis. Journal Of Invasive Cardiology 2006, 18: 309-12. PMID: 16816435.Peer-Reviewed Original ResearchConceptsDosimetric analysisDistal segmentsRadiation exposureDistal reference sitesStent restenosis casesSignificant serial changesGreater radiation exposurePositive vessel remodelingRestenosis casesBeta radiation exposureLumen lossPositive remodelingCoronary arteryPlaque volumeGeographic missPlaque areaDistal vasculatureSerial changesPlaque massPlaque increasePrescribed doseVessel changesMild increaseMinimum doseVessel remodelingAngiographic Results of the First Human Experience With the Biolimus A9 Drug-Eluting Stent for De Novo Coronary Lesions
Costa RA, Lansky AJ, Abizaid A, Müeller R, Tsuchiya Y, Mori K, Cristea E, Leon MB, Sousa JE, Schmidt T, Hauptmann KE, Grube E. Angiographic Results of the First Human Experience With the Biolimus A9 Drug-Eluting Stent for De Novo Coronary Lesions. The American Journal Of Cardiology 2006, 98: 443-446. PMID: 16893694, DOI: 10.1016/j.amjcard.2006.02.051.Peer-Reviewed Original ResearchConceptsNovo coronary lesionsCoronary lesionsDe novo coronary lesionsNoncomplex coronary lesionsLate lumen lossFirst human experienceDrug-eluting stentsAngiographic characteristicsAngiographic findingsAngiographic resultsLumen lossStent groupBaseline lesionsStent restenosisControl groupLesionsStentsUncoated stentsDistal edgeGroupPatientsHyperplasiaRestenosisEffect of Everolimus-Eluting Stents in Different Vessel Sizes (from the Pooled FUTURE I and II Trials)
Tsuchiya Y, Lansky AJ, Costa RA, Mehran R, Pietras C, Shimada Y, Sonoda S, Cristea E, Negoita M, Dangas GD, Moses JW, Leon MB, Fitzgerald PJ, Müller R, Störger H, Hauptmann KE, Grube E. Effect of Everolimus-Eluting Stents in Different Vessel Sizes (from the Pooled FUTURE I and II Trials). The American Journal Of Cardiology 2006, 98: 464-469. PMID: 16893698, DOI: 10.1016/j.amjcard.2006.02.054.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood Vessel Prosthesis ImplantationCoated Materials, BiocompatibleCoronary AngiographyCoronary RestenosisCoronary VesselsEverolimusFemaleFollow-Up StudiesHumansImmunosuppressive AgentsMaleMiddle AgedProspective StudiesProsthesis DesignSirolimusStentsTreatment OutcomeUltrasonography, InterventionalConceptsBare metal stentsDe novo coronary lesionsNovo coronary lesionsCoronary lesionsNeointimal proliferationStent late lumen lossMid-term outcomesLate lumen lossEverolimus-Eluting StentsQuantitative coronary angiographyMinimum lumen areaVessel sizeII trialCoronary angiographyI trialIncomplete appositionLumen lossStent thrombosisAneurysm formationStent restenosisIntravascular ultrasoundMetal stentsReference diameterLumen areaPatients
2005
Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial)
Costa RA, Lansky AJ, Mintz GS, Mehran R, Tsuchiya Y, Negoita M, Gilutz Y, Nikolsky E, Fahy M, Pop R, Cristea E, Carlier S, Dangas G, Stone GW, Leon MB, Müller R, Techen G, Grube E. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). The American Journal Of Cardiology 2005, 95: 113-116. PMID: 15619406, DOI: 10.1016/j.amjcard.2004.08.074.Peer-Reviewed Original ResearchConceptsCoronary lesionsDe novo coronary lesionsStent late lumen lossNoncomplex coronary lesionsSegment diameter stenosisNovo coronary lesionsLate lumen lossEverolimus-eluting stentsFirst human experienceMetallic stent groupEdge restenosisAngiographic characteristicsSegment restenosisAngiographic findingsAngiographic resultsStent thrombosisDiameter stenosisLumen lossStent groupAneurysm formationStent restenosisMetallic stentsRestenosisLesionsStents
2000
Vascular remodeling and the local delivery of cytochalasin B after coronary angioplasty in humans
Lehmann K, Popma J, Werner J, Lansky A, Wilensky R. Vascular remodeling and the local delivery of cytochalasin B after coronary angioplasty in humans. Journal Of The American College Of Cardiology 2000, 35: 583-591. PMID: 10716458, DOI: 10.1016/s0735-1097(99)00603-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryCatheterization, PeripheralCoronary AngiographyCoronary DiseaseCoronary VesselsCytochalasin BDrug Delivery SystemsElectrocardiographyFeasibility StudiesFemaleHumansInfusions, Intra-ArterialMaleMiddle AgedMyocardial RevascularizationSafetyTreatment OutcomeConceptsCoronary angioplastyLocal deliveryVascular remodelingMinimal stenosis diameterSuccessful balloon angioplastyCombined end pointActive drug groupSuccessful coronary angioplastyLate lumen lossCytochalasin BSystemic drug administrationWarrants further studyInadequate dosingPlacebo groupClinical restenosisPharmacologic preventionAngioplasty siteClinical outcomesBalloon angioplastyLumen lossDrug groupsArterial constrictionElectrocardiographic variablesStenosis diameterAtherosclerotic plaques